Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2022-A01483-40 | Other Identifier | ID-RCB number, ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In neuroinflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and anti-MOG antibody-associated disorders (MOGAD), neuronal degeneration is the consequence of inflammatory and demyelinating lesions in the brain, optic nerve and spinal cord. Both white and grey matter are systematically affected. Lesions of the perivascular spaces containing cerebrospinal fluid (CSF) and meningeal inflammation seem to play an important role in the pathophysiology of these neuroinflammatory diseases. Currently, the interrelation of all these aspects is not clearly established in the pathophysiology of these diseases. In order to better understand the mechanisms that lead to and underlie the clinical disability of patients with these diseases, we need in vivo study models that allow the in-depth study of the neurodegenerative process and the identification of its causes. In this perspective, we make the hypothesis that the visual pathways model is very relevant to measure neuro-axonal loss and to explore the different mechanisms involved in neurodegeneration during MS and other CNS demyelinating diseases. Researchers have at their disposal many tools that allow them to analyse and quantify the neurodegenerative process in a reproducible and very precise manner from a structural and functional point of view, while taking into account possible vascular involvement (MRI, optical coherence tomography - angiography, etc…).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| optic neuritis patients | Patients suffering from an acute episode of optic neuritis will be included. There will be only one group of patients prospectively followed-up. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clinical examen | Other | MRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition |
|
| Measure | Description | Time Frame |
|---|---|---|
| Presence of enhancement of the optic nerve sheath on the axial T1 dixon MRI sequence post gadolinium at the acute phase of optic neuritis. | at inclusion | |
| Low contrast monocular visual acuity (2.5%, LogMAR unit) at distance from acute optic neuritis | at 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Presence of enhancement of the optic nerve sheath on the axial T1 dixon MRI sequence post gadolinium. Macular GCIPL atrophy will be assessed by the variation of mGCIPL volume between inclusion and the maximal follow-up. | at inclusion and at 12 months follow-up | |
| Optic nerve lesion length on 3D-DIR sequence. Alteration of retinal microvascularisation between inclusion and the maximal follow-up. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
A history of pre-existing CNS inflammatory demyelinating disease is not a criterion for non-inclusion.
Not provided
Not provided
Patients presenting an episode of acute optic neuritis with the objective of better understanding the pathophysiology of CNS inflammatory diseases and identifying prognostic biomarkers in imaging
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Olivier OUTTERYCK, MD | Contact | 0320445962 | +33 | olivier.outteryck@chu-lille.fr |
| Name | Affiliation | Role |
|---|---|---|
| Olivier OUTTERYCK, MD | University Hospital, Lille | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hop Fontan Chu | Recruiting | Lille | 59037 | France |
Not provided
| ID | Term |
|---|---|
| D009902 | Optic Neuritis |
| D003711 | Demyelinating Diseases |
| ID | Term |
|---|---|
| D009901 | Optic Nerve Diseases |
| D003389 | Cranial Nerve Diseases |
| D009422 | Nervous System Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| at inclusion and at 12 months follow-up |
| Acute alteration of retinal microvascularisation is assessed by the difference of retinal vascular density between inclusion (V0) and one month later (V1). | at inclusion and at 1 months follow-up |
| Low contrast monocular visual acuity (2.5%, LogMAR unit) measured at 12 months (V5) | at inclusion and at 12 months follow-up |
| Amplitude of the melanopsin-mediated sustained constriction phase in the blue light-induced pupillary response is assessed at 12 months (V5). | at inclusion and at 12 months follow-up |
| Optic nerve lesion length assessed at inclusion (V0) | at inclusion |
| mGCIPL atrophy/retinal vascular alteration are assessed by mGCIPL volume/retinal vessel density difference between inclusion (V0) and at 12 months (V5). | at inclusion and at 12 months follow-up |
| Presence of leptomeningeal cerebral enhancement | at inclusion, at 6 months and at 12 months follow-up |
| T2 lesions brain and spinal cord volumes | at inclusion, at 6 months and at 12 months follow-up |
| Brain grey matter volumes and brain perfusion (3D-ASL) | at inclusion, at 6 months and at 12 months follow-up |